LISTING OF CLAIMS

1. (Original) A monoclonal antibody selected from the group consisting of:

(a) a monoclonal antibody Met3 produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-4349; and

(b) a monoclonal antibody Met5 produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-4477,

or an antigen binding fragment or derivative of said antibody.

Claims 2-3 CANCELLED

4. (*currently amended*) A monoclonal antibody, or antigen-binding fragment or derivative thereof, that has all the identifying biological characteristics of the monoclonal antibody, fragment or derivative of claim 1 [[2]].

Claim 5 CANCELLED

6. (*currently amended*) A humanized monoclonal antibody specific for Met, wherein

(a) the heavy chain and/or light chain variable region of said antibody, or an antigen binding site of said variable regions, has all the identifying biological or structural characteristics of the corresponding regions or sites of the monoclonal antibody of claim 1 ~~2 or 3,~~; and

(b) substantially all the remainder of the humanized monoclonal antibody is of human origin,

or an antigen binding fragment or derivative of said humanized monoclonal antibody.

7. (*currently amended*) A human monoclonal antibody specific for Met that binds to the same epitope as the epitope to which the monoclonal antibody of claim[[s]] 1 [[2]] binds, or an antigen binding fragment or derivative of said human antibody.

Claim 8 CANCELLED

9. (Original) A composition comprising the monoclonal antibody, fragment or derivative of claim 1.

Claims 10-11 CANCELLED

12. (*currently amended*) The composition of ~~any~~ claim 9[[-11]], further comprising one or more additional antibodies specific for a Met epitope, or comprising an antigen-binding fragment or derivative of said additional one or more antibodies.

13. (*currently amended*) The composition of ~~any of claims~~ claim 9[[-11]] further comprising one or more antibodies specific for hepatocyte growth factor (HGF), or comprising an antigen-binding fragment or derivative of said one or more HGF-specific antibodies.

14. (Original) The composition of claim 13 wherein the one or more antibodies specific for HGF is selected from the group consisting of:

(a) a monoclonal antibody produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3414;
(b) a monoclonal antibody produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3416;
(c) a monoclonal antibody produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3413; and
(d) a monoclonal antibody produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3412.

15. (*currently amended*) A diagnostically useful composition comprising

(a) ~~a diagnostically or detectably labeled~~ the monoclonal antibody, fragment or derivative of ~~any of claims~~ claim 1[[-8]] which is diagnostically or detectably labeled ~~and;~~
(b) a diagnostically acceptable carrier or excipient.

16. (*currently amended*) A diagnostically useful composition comprising

(a) ~~a diagnostically or detectably labeled~~ the composition of ~~any of claims~~ claim 9[[-11]] which is diagnostically or detectably labeled; and
(b) a diagnostically acceptable carrier or excipient.

17. (*currently amended*) A diagnostically useful composition comprising

(a) ~~a diagnostically or detectably labeled~~ the composition of claim 12 which is diagnostically or detectably labeled; and
(b) a diagnostically acceptable carrier or excipient.

18. (*currently amended*) A diagnostically useful composition comprising

(a) ~~a diagnostically or detectably labeled~~ the composition of claim 13 which is diagnostically or detectably labeled; and

(b) a diagnostically acceptable carrier or excipient.

19. (Original) The diagnostically useful composition of claim 15 wherein the monoclonal antibody, fragment or derivative is labeled with a detectable label selected from the group consisting of a radionuclide, a PET-imageable agent, a MRI-imageable agent, a fluorescer, a fluorogen, a chromophore, a chromogen, a phosphorescer, a chemiluminescer and a bioluminescer.

Claim 20 CANCELLED

21. (Original) The composition of claim 19 wherein the monoclonal antibody, fragment or derivative is labeled with a radionuclide.

22. (Original) The composition of claim 21 wherein said radionuclide is one which is detectable *in vivo*.

23. (Original) The composition of claim 22 wherein the radionuclide is detectable by radioimmunoscintigraphy.

24. (*currently amended*) The composition of claim 21 wherein the radionuclide is selected from the group consisting of ^{3}H, ^{14}C, ^{35}S, ^{99m}Tc, ^{123}I, ^{125}I, ^{131}I, ^{111}In, ^{97}Ru, ^{67}Ga, ^{68}Ga, ^{72}As, ^{89}Zr and ^{201}Tl.

25. (Original) The composition of claim 24 wherein the radionuclide is ^{125}I.

Claims 26-30 CANCELLED

31. (Original) The composition of claim 19 wherein the detectable label is a fluorescer or fluorogen.

32. (Original) The composition of claim 31 wherein the fluorescer or fluorogen is selected from the group consisting of fluorescein, rhodamine, dansyl, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine, a fluorescein derivative, Oregon Green, Rhodamine Green, Rhodol Green and Texas Red.

Claims 33-34 CANCELLED

35. (Original) The composition of claim 19 wherein said detectable label is bound to the antibody through one or more diethylenetriaminepentaacetic acid (DTPA) residues that are coupled to the antibody.

36. (Original) The composition of claim 35 wherein the detectable label is bound to the antibody through one DTPA residue.

37. (Original) The composition of claim 35 useful for MRI diagnosis wherein metal atoms are bound to said DTPA residues.

38. (Original) The composition of claim 37 wherein said metal is selected from the group consisting of gadolinium, manganese, copper, iron, gold and europium.

39. (Original) The composition of claim 38 wherein said metal is gadolinium.

Claims 40-44 CANCELLED

45. (*currently amended*) A therapeutic composition useful for treating a Met-expressing tumor, comprising:

(a) the monoclonal antibody, fragment or derivative of ~~any of claims~~ claim 1[[-8]] in a therapeutically effective amount, and

(b) a pharmaceutically or therapeutically acceptable carrier or excipient.

46. (*currently amended*) A therapeutic composition useful for treating a Met-expressing tumor, comprising:

(a) the composition of ~~any of claims~~ claim 9 [[-11]] in a therapeutically effective amount, and;

(b) a pharmaceutically or therapeutically acceptable carrier or excipient.

47. (Original) A therapeutic composition useful for treating a Met-expressing tumor, comprising:

(a) the composition of claim 12 in a therapeutically effective amount, and;

(b) a pharmaceutically or therapeutically acceptable carrier or excipient.

CLAIM 48 CANCELLED

49. (Original) The therapeutic composition of claim 45 in a form suitable for injection or infusion.

50. (Original) The therapeutic composition of claim 45, wherein at least one of the antibodies, fragments or derivatives is bound to, conjugated to, or labeled with a therapeutic moiety.

51. (Original) The therapeutic composition of claim 50 wherein the therapeutic moiety is a radionuclide.

52. (*currently amended*) The therapeutic composition of claim 51 wherein the radionuclide is selected from the group consisting of ^{47}Sc, ^{67}Cu, ^{90}Y, ^{109}Pd, ^{125}I, ^{131}I, ^{186}Re, ^{188}Re, ^{199}Au, ^{211}At, ^{212}Pb and [^{217}Bi] ^{212}Bi.

CLAIM 53-57 CANCELLED

58. (Original) The therapeutic composition of claim 47, wherein at least one of the antibodies, fragments or derivatives is bound to, conjugated to, or labeled with a therapeutic moiety.

59. (Original) The therapeutic composition of claim 58 wherein the therapeutic moiety is a radionuclide.

60. (*currently amended*) The therapeutic composition of claim 59 wherein the radionuclide is selected from the group consisting of ^{47}Sc, ^{67}Cu, ^{90}Y, ^{109}Pd, ^{125}I, ^{131}I, ^{186}Re, ^{188}Re, ^{199}Au, ^{211}At, ^{212}Pb and [^{217}Bi] ^{212}Bi.

Claims 61-64 CANCELLED

65. (*currently amended*) A kit, comprising:

(a) a labeled first container comprising the antibody, fragment or derivative of ~~any of claims~~ claim 1[[-8]];

(b) a labeled second container comprising a diagnostically or pharmaceutically-acceptable carrier or excipient; and

(c) instructions for using the antibody to diagnose, prognose, monitor or treat a cancerous condition or a tumor in a subject wherein cancer or tumor cells in said subject are known or suspected to express Met,

wherein the antibody, fragment or derivative is effective for diagnosing, prognosing, monitoring or treating said condition and

said labeled container indicates that the antibody can be used for said diagnosing, prognosing, monitoring or treating.

66. (Original) A method for detecting the presence of Met (i) on the surface of a cell, (ii) in a tissue, (iii) in an organ or (iv) in a biological sample, which cell, tissue, organ or sample is suspected of expressing Met, comprising the steps of:

(a) contacting the cell, tissue, organ or sample with the composition of claim 15;

(b) detecting the presence of the label associated with the cell, tissue, organ or sample.

Claims 67-69 CANCELLED

70. (Original) The method of claim 66, wherein the contacting and the detecting are *in vitro*.

71. (Original) The method of claim 66 wherein the contacting is *in vivo* and the detecting is *in vitro*.

72. (Original) The method of claim 66, wherein the contacting and the detecting are *in vivo*.

Claims 73-75 CANCELLED

76. (Original) The method of claim 72 wherein said detectable label is a radionuclide

Claims 77-79 CANCELLED

80. *(currently amended)* The method of claim 76 wherein the radionuclide is selected from the group consisting of ^{3}H, ^{14}C, ^{35}S, ^{99m}Tc, ^{123}I, ^{125}I, ^{131}I, ^{111}In, ^{97}Ru, ^{67}Ga, ^{68}Ga, ^{72}As, ^{89}Zr and ^{201}Tl.

Claims 81-83 CANCELLED

84. (Original) The method of claim 80 wherein said detecting is by radioimmunoscintigraphy.

Claims 85-87 CANCELLED

88. (Original) The method of claim 84 wherein the radionuclide is ^{125}I.

Claims 89-91 CANCELLED

92 (Original) The method of claim 72, wherein the detectable label is an MRI-imageable agent and the detecting is by MRI.

Claims 93-95 CANCELLED

96. (Original) A method for inhibiting (i) the proliferation, migration, or invasion of, Met-expressing tumor cells or (ii) angiogenesis induced by Met-expressing tumor cells, comprising contacting said cells with an effective amount of the therapeutic composition of claim 45.

Claims 97-99 CANCELLED

100. (Original) The method of claim 96 wherein the contacting is *in vivo*.

Claims 101-103 CANCELLED

104. (Original) The method of claim 100 wherein the therapeutic composition of is in a form suitable for injection or infusion.

105. (Original) The method of claim 100 wherein, in the therapeutic composition, at least one of the antibodies, fragments or derivatives is bound to, conjugated to, or labeled with a therapeutic moiety.

106. (Original) The method of claim 105 wherein, in the therapeutic composition, the therapeutic moiety is a radionuclide.

Claims 107--115 CANCELLED

116. (Original) A method for treating a subject having a cancerous disease or condition associated with (i) undesired proliferation, migration or invasion of Met-expressing cells or (ii) undesired angiogenesis induced by Met-expressing cells, comprising administering to the subject an effective amount of the therapeutic composition of claim 45.

Claims 117-119 CANCELLED

120. (Original) The method of claim 116 wherein, in the therapeutic composition, at least one of the antibodies, fragments or derivatives is bound to, conjugated to, or labeled with a therapeutic moiety.

Claims 121--123 CANCELLED

124. (Original) The hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-4349.

125. (Original) The hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-4477.